On January 13, 2014, Principal Investigator Charles Grob, M.D., received from the U.S. Drug Enforcement Administration the Schedule I pharmacy license for our new study of MDMA-assisted therapy for social anxiety in autistic adults. The license was issued on December 27, 2013. With this final regulatory permission in hand, Dr. Grob and co-investigator Alicia Danforth, Ph.D., are now creating the initial waiting list. The official study initiation is scheduled to take place from February 7-10, and the MDMA for the study will be encapsulated in mid-February.
